Is baricitinib up next for atopic dermatitis?

A M Drucker^{1

2}

Affiliations

¹ Division of Dermatology, Department of Medicine, University of Toronto, Canada.
² Women's College Research Institute and Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Canada.

Comment

A M Drucker. Br J Dermatol. 2020 Aug.

. 2020 Aug;183(2):199-200.

doi: 10.1111/bjd.19226. Epub 2020 Jul 13.

A M Drucker^{1

2}

¹ Division of Dermatology, Department of Medicine, University of Toronto, Canada.
² Women's College Research Institute and Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Canada.

No abstract available

Comment on

Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838

1. Roekevisch E, Spuls PI, Kuester D et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014; 133:429-38.
1. Sidbury R, Davis DM, Cohen DE et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71:327-49.
1. Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389:2287-303.
1. Simpson EL, Lacour J-P, Spelman L et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183:242-55.
1. Simpson EL, Bieber T, Guttman-Yassky E et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.